Drug intelligence / Profile preview

BHI Rejuve

Development stage: Preclinical
Lead developer: BHI Therapeutic Sciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Intrathecal, Intraarticular, Subcutaneous, Oral

Overview

BHI Rejuve is a preclinical-stage combination therapy program developed by BHI Therapeutic Sciences. It is designed to address conditions associated with aging and hormonal decline, including early menopause and low testosterone. The program utilizes a multi-modal approach that integrates hormone optimization, chelation therapy, and stem cell research protocols to promote rejuvenation and systemic health.

Brand names: BHI Rejuve

Beyond the preview

Go deeper on BHI Rejuve.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHI Rejuve.

Explore the full profile